Previously we demonstrated that anti-LFA-1 monoclonal (mAb) could promote long-term survival of discordant porcine islet xenografts in mice. The aim of this study, therefore, was to determine whether a shortterm administration of anti-LFA-1 mAb would promote long-term survival of concordant rat islet xenografts in mice, and whether combining short-term administration of anti-LFA-1 mAb therapy with an immunosuppressive drug, rapamycin, would facilitate islet xenograft survival. Streptozotocin-induced diabetic BALB/c mice were transplanted with 500 Wistar-Furth rat islets under the kidney capsule and were either left untreated or treated with short-term administration of rapamycin (0.2 mg/kg) alone, anti-LFA-1 mAb (0.2 mg/ dose) alone, or a combination of rapamycin and anti-LFA-1 mAb using the same doses. All untreated mice rejected their grafts by 24 days posttransplantation with a mean graft survival time of 18.8 ± 2.5 days posttransplantation (n = 5). All mice treated with rapamycin alone had prolonged islet graft survival but eventually rejected their islet grafts by 81 days posttransplantation. In contrast, the majority of the mice (27/ 28) treated with anti-LFA-1 mAb alone maintained long-term normoglycemia (>100 days). Rapamycin in combination with anti-LFA-1 mAb proved equally effective with 29 of 30 mice maintaining normoglycemia for more than 100 days posttransplantation. Low levels of mouse anti-rat antibodies, as well as a decrease in the degree of mononuclear cell infiltration of the islet graft, closely correlated with long-term islet xenograft survival. These results demonstrate that monotherapy with anti-LFA-1 mAb is highly effective in promoting long-term survival of rat islet xenografts and that combination of anti-LFA-1 mAb with rapamycin does not facilitate nor abrogate the induction of long-term xenograft survival by anti-LFA-1 mAb therapy in BALB/c mice. Our study indicates that immunomodulation through mAb therapy could form a significant component of future antirejection therapies in clinical islet xenotransplantation.
INTRODUCTION
ponents of the immune system or target cell surface adhesion molecules (34) . One mAb of particular interest is anti-leukocyte function associated antigen-1 (anti-The success of the Edmonton Protocol has placed islet transplantation in the spotlight as a viable alternative LFA-1), which binds to LFA-1 (CD11a/CD18), a member of a family of structurally and functionally similar for the treatment of type 1 diabetes mellitus (T1DM), a chronic metabolic disorder characterized by the autoim-leukocyte differentiation antigens that is involved in the homing, adhesion, and activation of lymphocytes (18, mune destruction of the insulin-producing β-cells of the pancreas (27) . At present, the widespread clinical appli -20) . Antibodies directed towards LFA-1 have been shown to be beneficial in preventing islet allograft and cation of islet transplantation is limited by the shortage of human donors and the continuous administration of discordant islet xenograft rejection (4, 7, 16, 17, 21, 29) .
Recently, a humanized form of anti-LFA-1, Efalizumab, immunosuppressive drugs to prevent rejection (1, 11, 28, 31) . Thus, the use of monoclonal antibodies (mAbs) to was approved for phase IV trials for the treatment of psoriasis (15). prevent the immune rejection of transplanted tissue is quickly becoming a vital component of therapy in differ-
The aim of this study was to examine the efficacy of a short-term therapy of anti-LFA-1 mAb in preventing ent types of transplantation (3, 8, 24, 25) . Monoclonal antibodies can be used to deplete or inhibit specific com-the rejection of rat islet xenografts in immune competent mice, a concordant donor/recipient combination, to elu-essential medium (EMEM, Invitrogen, Burlington, ON, Canada) supplemented with 10% fetal bovine serum (In-cidate the importance of LFA-1 in the rejection of rat islet xenografts. In addition, this study also investigated vitrogen), 1 × 10 −5 M 2-mercaptoethanol, L-glutamine, and 1% antibiotics were prepared in 96-well flat-bottom whether treatment with rapamycin would result in improved or inferior islet xenograft survival. Rapamycin is plates and incubated at 37°C, 5% CO 2 , and 95% air. After 3-, 4-, and 5-day incubation periods, T-cell prolif-of particular interest because it is one of the immunosuppressive drugs used in clinical islet transplantation (31). eration was detected by pulsing the cells of primary culture with 1 µCi [ 3 H]thymidine (GE Healthcare, Piscata-Rapamycin prevents the proliferation of T and B lymphocytes by inhibiting mTOR. mTOR has a crucial role way, NJ, USA) for 22 h on the indicated day of culture. Cells were harvested onto glass microfiber filters (Wal-in the regulation of protein synthesis and translation initiation. Rapamycin consequently inhibits protein synthe-lac, Turku, Finland) and proliferation of cells was quantified using a Wallac beta emission counter (Wood-sis, arresting the cell in the G 1 phase of the cell cycle (5, 9, 13, 26) . Immunosuppressive drugs have largely been bridge, ON, Canada). Nonspecific mitogen stimulation with concanavalin A (ConA; 10 µg/ml, Sigma, Oakville, thought to be tolerance "unfriendly" (6); however, recent evidence suggests that rapamycin may be beneficial ON, Canada) served as a positive control. to the induction of transplantation tolerance (30) . There-Islet Isolation and Transplantation fore, examining the efficacy of conventional immunosuppressive drugs in combination with a biologic agent Wistar-Furth rat islets were isolated as previously described (23) . Briefly, rat pancreases were distended with as potential therapies to prevent xenograft rejection is essential to the success of islet xenotransplantation.
cold Hank's balanced salt solution (HBSS, Invitrogen) medium, followed by collagenase (Sigma) digestion and MATERIALS AND METHODS density gradient centrifugation with dextran (Sigma).
Animals
Isolated islets were then handpicked and cultured overnight in Hams F10 medium (Invitrogen) at 37°C, 5% Inbred male BALB/cByJ (BALB/c, H-2 d ) were pur-CO 2 , and 95% air. A total of 500 isolated islets were chased from the Jackson Laboratory (Bar Harbor, ME, transplanted under the left kidney capsule of diabetic USA) and Wistar-Furth (WF, RT1 U ) rats were purchased BALB/c mice as previously described (12). Engraftment from Harlan Laboratories (Indianapolis, IN, USA). Rewas considered successful when the blood glucose level cipient BALB/c mice were rendered diabetic by a single decreased to <10 mmol/L. Graft rejection was defined IP injection of streptozotocin (250 mg/kg body weight;
as the first of 3 consecutive days of hyperglycemia (>12 Sigma-Aldrich, Oakville, ON, Canada) 4-5 days before mmol/L glucose level) and confirmed by histological transplantation. All diabetic recipients had two consecuanalysis of the grafts. A survival nephrectomy of the tive nonfasting blood glucose levels >17 mmol/L. The graft-bearing kidney was performed on randomly seblood glucose of each recipient mouse was monitored lected recipients with long-term normoglycemia (>100 by taking blood samples from the tail vein and glucose days posttransplantation), to confirm that normal blood levels were measured using a OneTouch Ultra glucoglucose levels were due to the islet transplants. meter (LifeScan, Burnaby, BC, Canada). All animals were housed under pathogen-free conditions and fed Antirejection Therapies standard laboratory food and water ad libitum, and cared Transplant recipients were randomly designated to refor according to the guidelines established by the Canaceive the following antirejection treatments intraperitodian Council on Animal Care. neally: 1) rapamycin alone (0.2 mg/kg on days 0 through In Vitro Proliferation Assays 14 posttransplantation; a generous gift from Dr. James Shapiro, Edmonton, AB, Canada), 2) anti-LFA-1 mAb Single cells from lymph node (responders) and spleen (stimulators) were prepared by mechanical disruption of alone (KBA; rat IgG2a; 0.2 mg on days 0, 1, 7, 14, 21, and 28 posttransplant), and 3) rapamycin (0.2 mg/kg on lymph nodes and spleen between rough edges of sterile glass slides. Red blood cells from the spleen cell suspen-days 0 through 14 posttransplantation) plus anti-LFA-1 mAb (0.2 mg on days 0, 1, 7, 14, 21, and 28 posttrans-sion were depleted by incubation of the cells in red cell lysing buffer for 4 min at room temperature. Mixed lym-plant). Untreated transplanted recipients served as the control for this experiment. phocyte cultures were prepared by combining 5 × 10 5 BALB/c lymph node cells/well with 1 × 10 6 irradiated Immunohistochemical Staining (2500 rads) WF rat spleen cells/well with or without rapamycin (2.5 µg/ml), anti-LFA-1 mAb (50 µg/ml), or Sections 5 µm thick of formalin-fixed tissues were stained to determine the presence of insulin containing a combination of both using the same doses. Triplicate cultures in a total volume of 0.2 ml of Earl's minimum β-cells. Insulin-containing β-cells were detected by applying guinea pig anti-porcine insulin primary anti-rat spleen cells, and rat spleen cells stained with secondary antibody alone without mouse serum. body (1:1000; DAKO Corporation, Carprinteria, CA, USA) for 30 min, followed by the addition of biotinyl-Statistical Analysis ated goat anti-guinea pig IgG secondary antibody (1: Statistical differences between treatment groups in 200; Vector Laboratories, Burlingame, CA, USA). The mixed lymphocyte culture assays and mouse anti-rat IgG avidin-biotin complex/horseradish peroxidase (ABC/ antibody levels were determined using Univariate Anal-HP; Vector Laboratories) and 3,3-diaminobenzidinetetysis of Variance. Statistical differences in graft survival rahydrochloride (DAB; BioGenex, San Ramon, CA, among groups were analyzed using the Kaplan-Meier USA) was used to produce a brown color. All sections Log rank test. All statistical tests were performed using were counterstained with Harris' hematoxylin and eosin.
SPSS statistical software, version 13.0 for Windows Subpopulations of T cells (CD4 + and CD8 + ) and mac-(Chicago, IL, USA). A value of p < 0.05 in all tests was rophages (CD11b + ) were also determined on tissues imconsidered to be statistically significant. mersed in optimum cutting temperature (OCT) compound (Fisher Scientific, Ottawa, ON, Canada) and snap RESULTS frozen at −80°C. Sections 5µm thick of tissue were air Treatment With Anti-LFA-1 mAb and/or Rapamycin dried for 10 min and then fixed in acetone for 3 min Inhibits the In Vitro Proliferation of Lymphocytes at 4°C. These sections were then washed in PBS and nonspecific binding was eliminated by incubating the BALB/c mouse lymphocytes were stimulated with irtissue sections in 2% FBS/PBS for 20 min. In addition, radiated WF rat spleen cells with or without the addition endogenous biotin or biotin binding proteins present in of anti-LFA-1 mAb, rapamycin, or a combination of the sections were also eliminated using the avidin/biotin anti-LFA-1 mAb and rapamycin to determine the effect blocking kit (Vector Laboratories, Inc.). Rat anti-mouse of anti-LFA-1 mAb and/or rapamycin on the prolifera-CD4 antibody (1:100; BD Pharmingen, Mississauga, tive response of mouse lymphocytes in vitro. Stimula-ON, Canada), rat anti-mouse CD8b antibody (1:100; BD tion of BALB/c mouse lymphocytes with rat spleen cells Pharmingen), or rat anti-mouse CD11b antibody (1:500; resulted in robust proliferation after 3, 4, and 5 days of BD Pharmingen) was applied to designated sections for culture (30,573 ± 1,871, 37,645 ± 3,916, and 19,816 ± 30 min at room temperature. Biotinylated rabbit anti-1,567 cpm, respectively) (Table 1) . Similarly, stimularat IgG secondary antibody (1:200; Vector Laboratories, tion of BALB/c mouse lymphocytes with ConA resulted Inc.) was added and incubated for 20 min. The ABC/HP in vigorous proliferation after 3, 4, and 5 days in culture reagent (Vector Laboratories, Inc.) was applied, and (Table 1) . However, addition of anti-LFA-1 mAb, rapa-DAB (BioGenex) was used to produce a brown color. mycin, or both treatments to the mixed cell cultures re-Sections were counterstained with Harris' hematoxylin.
sulted in significant reduction in the proliferative response of BALB/c mouse lymphocytes compared to the Determination of Anti-Rat Antibodies response observed after stimulation without treatment by Flow Cytometry (p < 0.05, days 4 and 5; n = 3) ( Table 1 ). The combina-The effect of anti-LFA-1 mAb and/or rapamycin tion of anti-LFA-1 mAb and rapamycin had no additive therapy on the production of mouse anti-rat antibodies inhibitory effect on lymphocyte proliferation and the rewas determined by flow cytometry. Peripheral blood sponses were comparable to the responses observed samples from BALB/c mouse recipients were collected when both treatments were administered alone. These at the time of rejection or following long-term islet xeresults show that anti-LFA-1 mAb and rapamycin alone nograft survival. The serum was isolated by incubation appeared equally effective at inhibiting the in vitro proof blood samples at room temperature for at least 1 h, liferation of lymphocytes and that a combination of both followed by centrifugation at 10,000 rpm for 10 min.
did not increase or decrease the inhibitory effect of indi-Wistar-Furth rat spleen cells (1 × 10 6 ) were incubated vidual treatment. with mouse serum at 1:128 dilution for 1 h at 37°C, 5%
Anti-LFA-1 mAb Alone or in Combination CO 2 , 95% air. Spleen cells were then washed with PBS With Rapamycin Prevents the Rejection and incubated with FITC-conjugated goat anti-mouse of Rat Islet Xenografts IgG antibody (rat adsorbed, 1:100; Southern Biotechnology Associates, Inc., Birmingham, AL, USA) for 1 h at We next examined the effect of anti-LFA-1 mAb and/or rapamycin in preventing the rejection of rat islet 4°C. The percentage of cells bound to antibody was detected from single-parameter fluorescence histograms on xenografts in vivo. Transplantation of WF rat islets into streptozotocin-induced diabetic BALB/c mice resulted a BD FACS Calibur (BD Bioscience) after gating on viable lymphocytes. Controls for this experiment include in the reversal of diabetes in all recipients within 5 days posttransplantation. Untreated recipients rapidly rejected sera from nontransplanted naive BALB/c mice, unstained their islet grafts by day 24 posttransplantation. In mice was observed compared to monotherapy of anti-LFA-1 mAb, and 29 of 30 recipients maintained normogly-treated with rapamycin alone, however, there was a modest prolongation of islet xenograft survival, but by cemia for over 100 days posttransplantation (p < 0.05 vs. untreated) ( Table 2 ). Removal of the graft-bearing day 81 posttransplantation all recipients eventually rejected their grafts (p < 0.05 vs. untreated) ( Table 2 ). In kidneys from randomly selected recipients resulted in the rapid return to a hyperglycemic state. recipients treated with anti-LFA-1 mAb alone, a significant prolongation of islet graft survival was observed and 27 of 28 recipients maintained normoglycemia for Anti-LFA-1 mAb Alone or in Combination With over 100 days posttransplantation (p < 0.05 vs. un-Rapamycin Is Associated With a Reduction treated) ( Table 2 ). In addition, treatment with anti-LFAin Lymphocyte Infiltration of the Islet Grafts 1 mAb alone significantly (p < 0.05) prolonged islet xenograft survival over rapamycin alone-treated mice Following rejection or after 100 days posttransplantation if mice maintained long-term normoglycemia, islet ( Table 2) . When anti-LFA-1 mAb was combined with rapamycin, no significant difference in graft survival xenografts were collected for histological examination Rapamycin (0.2 mg/kg) was administered on the day of transplantation (day 0) and every day thereafter for 2 weeks. Anti-LFA-1 mAb (0.2 mg/dose) was administered on day 0, 1, 7, 14, 21, and 28. Kaplan-Meier log rank test was used to determine statistical significance between groups. A p-value <0.05 was considered statistically significant. There was no significant difference found between anti-LFA-1 mAb alone-treated mice and mice receiving anti-LFA-1 mAb and rapamycin. *p < 0.05 no treatment versus treated groups. †p < 0.05 rapamycin versus no treatment, anti-LFA-1 mAb, and the combination treatment. ‡p < 0.05 anti-LFA-1 mAb versus no treatment and rapamycin. §p < 0.05 combination treatment versus no treatment and rapamycin.
ANTI-LFA-1 MONOCLONAL ANTIBODY PREVENTS RAT ISLET REJECTION 603 and identification of the immune cells infiltrating the tion, treatment with anti-LFA-1 mAb alone was associated with a marked decrease in the level of cellular infil-grafts. Histological examination of grafts from untreated mice showed no insulin-positive β-cells and a large in-tration of the grafts. Grafts from mice treated with the combination of anti-LFA-1 mAb and rapamycin con-flux of mononuclear cells was present at the site of the graft (Fig. 1A) . Similarly, in rapamycin-treated mice, tained robust insulin staining (Fig. 1D ). This treatment was also associated with a profound decrease in cellular virtually no insulin staining was detected and a large influx of cells was present within the graft (Fig. 1B) . In infiltrate, although this finding was not absolute.
In an effort to characterize the infiltrating cells pres-contrast, treatment of recipients with anti-LFA-1 mAb alone was successful in promoting long-term islet xeno-ent in the graft we also determined the presence of CD4 + and CD8 + T cells, as well as macrophages (CD11b + graft survival and was associated with a huge amount of insulin-positive β-cells in the graft (Fig. 1C) . In addi-cells). A significant amount of CD4 + T cells was de- Figure 1 . Well-preserved intact islet xenografts detected in mice treated with anti-LFA-1 mAb or in combination with rapamycin. Insulin staining and histological examination of the xenografts at the time of rejection or >100 days posttransplantation retrieved from untreated recipients showed virtually no insulin-positive cells (brown stain) and a large infiltration of mononuclear cells (A). Dispersed insulin-positive staining was detected in the grafts from rapamycin-treated mice and a large cellular influx (B). Extensive insulin-positive staining as well as a significant reduction in the level of cellular infiltration was present in anti-LFA-1 mAb-treated recipients (C). Long-term graft survival of mice treated with anti-LFA-1 mAb in combination with rapamycin was associated with robust insulin-positive staining and a marked reduction in the infiltration of the islet graft (D). Scale bar: 100 µm.
tected in the grafts of untreated mice and this finding or in combination with rapamycin greatly reduced the extent of CD11b + cellular infiltration (Fig. 2) . was consistent with the grafts of rapamycin alonetreated mice (Fig. 2) . CD4 + T cells were also present in Treatment With Anti-LFA-1 mAb Alone the grafts of mice treated with anti-LFA-1 mAb alone or a Combination of Anti-LFA-1 mAb or in combination with rapamycin but to a lesser extent and Rapamycin Is Associated With a compared to the untreated and rapamycin-treated Reduction in Mouse Anti-Rat Antibody Levels groups. Consistent with the length of graft survival, in groups that received no treatment or rapamycin alone, a Sera from recipients were analyzed to determine the effect of the various treatments on the production of greater amount of CD8 + T cells could be detected compared to the grafts from mice treated with anti-LFA-1 mouse anti-rat IgG antibodies using flow cytometry. In untreated recipient mice, there was a significant increase mAb or in combination with rapamycin, where the extent of CD8 + T-cell infiltration within the graft was abro-in the levels of mouse anti-rat IgG antibodies compared to the nontransplanted naive mice (Fig. 3A and B ). We gated (Fig. 2) . Untreated or mice treated with rapamycin alone did not prevent the recruitment of CD11b + cells to detected 67.7 ± 11.2% (n = 5) of rat spleen cells were bound to mouse IgG antibodies in mice receiving no the graft site. However, treatment with anti-LFA-1 mAb Figure 2 . Immunohistochemical analysis of islet grafts from various treatment groups, for characterization of infiltrating mononuclear cells. CD4 + and CD8 + T cells as well as macrophages (CD11b + ) were identified using antibodies specific to these cell markers. Cells expressing the specific markers are shown as brown structures. Scale bar: 100 µm. treatment (p < 0.05 vs. nontransplanted naive BALB/c). Treatment with rapamycin significantly (p < 0.05) decreased the production of antibodies compared to the untreated group; however, we still detected 39.8 ± 4.9% (n = 4) of rat spleen cells bound to mouse IgG antibodies (Fig. 3C) . In contrast, treatment with anti-LFA-1 mAb alone or in conjunction with rapamycin resulted in a significant (p < 0.05 vs. untreated transplanted and rapamycin alone-treated BALB/c mice) decrease in the production of mouse anti-rat IgG antibodies (14.8 ± 1.8%, n = 6 and 14.9 ± 0.9%, n = 28, respectively) ( Fig.  3D and E) . The levels of anti-rat IgG antibodies in anti-LFA-1 mAb alone or in combination with rapamycintreated recipient mice were similar to the levels detected in nontransplanted naive BALB/c mice (10.8 ± 0.6%, n = 7).
DISCUSSION
We have previously shown that LFA-1 has been identified to have a major role in discordant islet xenograft rejection (14, 21) , and rapamycin has been shown to be effective in preventing the rejection of islet allografts in clinical transplantation (31). However, the efficacy of anti-LFA-1 mAb and rapamycin in preventing rejection of concordant islet xenografts has been relatively undetermined. Therefore, the aim of the present study was to determine the efficacy of a short-term therapy with anti-LFA-1 mAb or rapamycin on the survival of rat islet xenografts and whether combining anti-LFA-1 mAb therapy with rapamycin would have a beneficial or detrimental effect on islet xenograft survival.
We initially performed mixed lymphocyte reaction (MLR) assays to determine the effect of anti-LFA-1 mAb, rapamycin, or a combination of both treatments on the proliferation of lymphocytes in vitro. We found a marked decrease in the proliferation of lymphocytes when anti-LFA-1 mAb, rapamycin or combination of both treatments was added to the cell cultures compared to the untreated or ConA-stimulated lymphocytes, which exhibited a robust proliferative response. These results rapamycin (14.9 ± 0.9%, n = 28) (E) resulted in a significant Treatment with rapamycin alone did prolong islet xenodecrease (p < 0.05 vs. untreated and rapamycin alone) in the graft survival; however, all recipients eventually rejected production of mouse anti-rat IgG antibodies. The levels of their grafts by day 81 posttransplantation and anti-rat mouse anti-rat IgG antibodies in these recipients were similar to the levels detected in nontransplanted naive BALB/c mice antibodies could be detected in the sera of these mice. approximately 97% of recipients (29 of 30 mice), indi-preventing rejection of discordant islet xenografts may not necessarily be as effective at preventing the rejection cating the majority of the beneficial effect of the combination therapy is attributed to anti-LFA-1 mAb therapy.
of concordant islet xenografts. For example, we previously reported that short-term administration of anti-In addition, treatment with anti-LFA-1 mAb alone significantly reduced the production of anti-rat antibodies LFA-1 mAb or a combination of anti-LFA-1 mAb and rapamycin was moderately effective in promoting long-in recipient mice similar to what was observed in mice treated with the combination therapy. The combination term survival of neonatal porcine islet xenografts (21) .
In that study, we also showed that none of the recipient therapy and anti-LFA-1 mAb alone also significantly prevented the infiltration of the islet xenografts by mo-mice treated with rapamycin achieved and maintained normoglycemia posttransplantation. In contrast, the cur-nonuclear cells. While some mononuclear cellular infiltrate could be detected in grafts from mice treated with rent study shows that anti-LFA-1 mAb or a combination of anti-LFA-1 mAb and rapamycin was highly effective anti-LFA-1 mAb alone and in combination with rapamycin, the majority of the grafts displayed a marked in preventing the rejection of rat islet xenografts. In addition, rapamycin was moderately effective in promoting reduction in the level of infiltration and robust insulin staining compared to the grafts from mice treated with survival of these islets. One may speculate that the differences in the strain of recipients used in this study rapamycin or mice receiving no treatment. Conversely, in the grafts of mice that failed to maintain normogly-(BALB/c) compared to our previous study (C57BL/6) may have contributed to the differences in the results. cemia, large influxes of CD4 + T cells and CD11b + cells were detected, indicating the importance of T helper However, our previous data showed that C57BL/6 mice transplanted with Wistar-Furth rat islets and treated with cells and macrophages in the rejection of rat islet xenografts. Furthermore, the increased production of anti-rat a combination of anti-LFA-1 mAb and rapamycin had significant long-term graft survival (data not shown). antibody in recipients that rejected the grafts and the corresponding lack of antibody production in mice with Because the rejection of rat islet xenografts is dependent on both direct and indirect pathways of antigen rec-long-term graft survival suggest a key mechanism of antibody-mediated graft rejection in this model. Indeed, ognition (22), our therapy was aimed at preventing both of these pathways. We demonstrated in vitro that anti-other studies have also found that costimulation blockade modulates the antibody response and helps maintain LFA-1 mAb inhibits the proliferation of lymphocytes and prevents graft rejection in vivo, where the indirect graft function (35).
Neonatal porcine islets have been described as a suit-antigen presentation dominates. In addition, the inhibition of anti-rat antibody production in recipient mice able alternative source of insulin-producing tissue for clinical transplantation (10, 12) , and currently represents treated with anti-LFA-1 mAb suggests that anti-LFA-1 mAb therapy successfully interrupts the indirect path-one the most promising sources of islets to meet the high demand for human islet transplantation. Many experi-way of antigen presentation. This is substantiated by the fact that T-cell-dependent antibody responses to xeno-mental models that are used implement porcine islets transplanted into mouse recipients, representing a dis-grafts are inferred evidence of indirect antigen recognition because B-cell activation requires the assistance of cordant relationship (33) . If porcine islets are to become a source of pancreatic tissue in human islet transplanta-T helper cells. Rapamycin, being a general immunosuppressant, is effective at inhibiting cell proliferation, in-tion where the relation is not as phylogenetically disparate, it is important to compare the mechanism of graft cluding T helper cells and, consequently, reduces the activation both directly and indirectly of various effector rejection as the relationship between the donor and recipient goes from discordant to concordant or vice versa.
populations including cytotoxic T cells, B cells, NK cells, and macrophages, which can potentially contribute Therefore, we performed the present study which represents a concordant xenogeneic islet transplantation, to to graft rejection (5, 13, 26) . Additionally, because rapamycin acts as a general immunosuppressant, following compare the immune response with that of a discordant islet transplantation which has been previously reported treatment, both host and donor immune cells are inhibited. This has immediate implications for both the direct by our group (21) . Previous studies have demonstrated the importance of CD4 + T cells in discordant porcine and the indirect pathways of antigen recognition. Because the lifetime of naive passenger leukocytes is lim-islet xenograft rejection, with an emphasis on the indirect pathway of antigen presentation (19, 22) . Although ited, treatment with rapamycin for 2 weeks effectively suppresses the direct pathway, to some extent, in our it has been suggested that the indirect pathway appears to maintain a significant role in the rejection process model. However, despite these effects of rapamycin, we observed no additional benefit to graft survival when (32) , it has been reported that as the relation between donor and recipient becomes more concordant, the direct compared to monotherapy with anti-LFA-1 mAb.
In conclusion, our study demonstrates the efficacy of pathway of antigen presentation is increasingly active in graft rejection (2) . Therefore, therapies effective at a monotherapy with anti-LFA-1 mAb in promoting the 
